Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
T Kongnakorn, T Lanitis, L Annemans, V Thijs… - Clinical drug …, 2015 - Springer
Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
[引用][C] Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and …
T Kongnakorn, T Lanitis, L Annemans… - Clinical drug …, 2014 - difusion.ulb.ac.be
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
T Kongnakorn, T Lanitis, L Annemans… - Clinical Drug …, 2015 - europepmc.org
Methods A previously published Markov model was adapted to the Belgian healthcare
setting. Clinical events modelled include ischaemic and haemorrhagic stroke, systemic …
setting. Clinical events modelled include ischaemic and haemorrhagic stroke, systemic …
Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
T Kongnakorn, T Lanitis, L Annemans, V Thijs… - Clinical Drug …, 2015 - infona.pl
Background and Objective Management of non-valvular atrial fibrillation (NVAF) focuses on
the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist …
the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist …
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
T Kongnakorn, T Lanitis, L Annemans… - Clinical drug …, 2015 - pubmed.ncbi.nlm.nih.gov
Background and objective Management of non-valvular atrial fibrillation (NVAF) focuses on
the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist …
the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist …
Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
T Kongnakorn, T Lanitis, L Annemans… - Clinical Drug …, 2015 - search.proquest.com
Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
T Kongnakorn, T Lanitis, L Annemans, V Thijs… - CLINICAL DRUG …, 2015 - lib.ugent.be
Background: Management of non-valvular atrial fibrillation (NVAF) focuses on the use of
anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist (VKA) …
anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist (VKA) …
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
T Kongnakorn, T Lanitis, L Annemans… - CLINICAL DRUG …, 2015 - biblio.ugent.be
Background: Management of non-valvular atrial fibrillation (NVAF) focuses on the use of
anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist (VKA) …
anticoagulation to mitigate the risk of stroke. Until recently, vitamin K antagonist (VKA) …